Neurocrine Stock Soars 14%, Adding $2 Billion, After Sales Top $1 Billion And Ingrezza Outlook Rises
Crenessity sales more than doubled and the Ingrezza forecast moved up, while a new Vykat patient death raised the reported toll to eight.
Neurocrine Biosciences, the San Diego drugmaker, saw its shares climb 13.56% to $165.06 in Tuesday trading as of 10:05 a.m. ET, adding about $2 billion in market value. Revenue grew 41% to $1.1 billion. It also raised its 2026 Ingrezza forecast, even as safety questions about its newly acquired Vykat drug lingered.
Crenessity doubles, Ingrezza adds 17%
Crenessity sales more than doubled to $211 million. Ingrezza reached $801 million, and the 2026 Ingrezza outlook now stands at $2.9 billion to $2.925 billion.
Adjusted third-quarter profit came to $347 million, up from $222 million a year earlier, according to the company's filing. The quarter was the company's first with more than $1 billion in net product sales.
Neurocrine develops and sells drugs across neurology, psychiatry, endocrinology and immunology. Its approved products treat tardive dyskinesia, Huntington's chorea and classic congenital adrenal hyperplasia, a rare hormone disorder. Ingrezza net product sales were $2.51 billion for 2025, and Crenessity sales were $301.2 million.
Vykat's safety record and the Soleno deal
The quarter also carried $107 million in sales of Vykat XR. A newly confirmed patient death brought the reported toll to eight, BioSpace reported.
Neurocrine bought Vykat through its $2.9 billion acquisition of Soleno Therapeutics in April, so the drug's safety record bears directly on what that deal delivers. The company plans a new study in 2027 on dosing and safety in Prader-Willi patients with complex health issues.
A rally against a lagging year
The stock was on pace for its biggest one-day gain in at least 275 trading sessions, the last comparable one coming on Sept. 30, 2025.
As of Monday's close, the shares were up about 3% year to date, trailing the S&P 500's gain of about 10%. They sat 22% below their highest close of the past year, set on July 30.
Neurocrine's 2027 study of Vykat dosing and safety in Prader-Willi patients with complex health issues is the next marker for the drug.
Sources
- Neurocrine: Q3 Earnings Snapshot — Associated Press
- Neurocrine defends Prader-Willi drug after another patient death - BioSpace — biospace.com
- Neurocrine Biosciences Non-GAAP EPS of $3.29 beats by $0.54, revenue of $1.12B beats by $80M (NBIX:NASDAQ) | Seeking Alpha — seekingalpha.com
- Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say — Yahoo Finance
- Neurocrine: Q3 Earnings Snapshot – WTOP News — wtop.com
- The company's filing (Neurocrine Biosciences) — SEC filing
- Neurocrine Biosciences — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR